Broz, P., Pelegrín, P. & Shao, F. The gasdermins, a protein household executing cell loss of life and irritation. Nat. Rev. Immunol. 20, 43–157 (2020).
Shi, J. et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell loss of life. Nature 526, 660–665 (2015).
Ding, J. et al. Pore-forming exercise and structural autoinhibition of the gasdermin household. Nature 535, 111–116 (2016).
Wang, Q. et al. A bioorthogonal system reveals antitumour immune perform of pyroptosis. Nature 579, 421–426 (2020).
Zhou, B. et al. Tom20 senses iron-activated ROS signaling to advertise melanoma cell pyroptosis. Cell Res. 28, 1171–1185 (2018).
Wang, Y. et al. Chemotherapy medicine induce pyroptosis by way of caspase-3 cleavage of a gasdermin. Nature 547, 99–103 (2017).
Li, F. et al. mRNA lipid nanoparticle-mediated pyroptosis sensitizes immunologically chilly tumors to checkpoint immunotherapy. Nat. Commun. 14, 4223 (2023).
Ploetz, E. et al. Steel–natural framework nanoparticles induce pyroptosis in cells managed by the extracellular pH. Adv. Mater. 32, 1907267 (2020).
Ngai, W. S. C. et al. Bioorthogonally activatable base enhancing for on-demand pyroptosis. J. Am. Chem. Soc. 144, 5411–5417 (2022).
Li, M. et al. Photoredox catalysis could also be a normal mechanism in photodynamic remedy. Proc. Natl Acad. Sci. USA 119, e2210504 (2022).
Yu, L. et al. Photocatalytic superoxide radical generator that induces pyroptosis in most cancers cells. J. Am. Chem. Soc. 144, 11326–11337 (2022).
Chen, B. et al. A pyroptosis nanotuner for most cancers remedy. Nat. Nanotechnol. 17, 788–798 (2022).
Su, X. et al. Disruption of zinc homeostasis by a novel platinum(IV)-terthiophene advanced for antitumor immunity. Angew. Chem. Int. Ed. 135, e202216917 (2022).
Zhang, W. et al. Bioorthogonal disruption of pyroptosis checkpoint for high-efficiency pyroptosis most cancers remedy. J. Am. Chem. Soc. 145, 16658–16668 (2023).
Liu, X. et al. Apoptosis-amplified meeting of porphyrin nanofiber enhances photodynamic remedy of oral tumor. J. Am. Chem. Soc. 145, 7918–7930 (2023).
Li, M. et al. Photon-controlled pyroptosis activation (PhotoPyro): an rising set off for antitumor immune response. J. Am. Chem. Soc. 145, 6007–6023 (2023).
Chauhan, V. & Jain, R. Methods for advancing most cancers nanomedicine. Nat. Mater. 12, 958–962 (2013).
Sindhwani, S. et al. The entry of nanoparticles into strong tumours. Nat. Mater. 19, 566–575 (2020).
Tu, Y. et al. Mimicking the cell: bio-inspired capabilities of supramolecular assemblies. Chem. Rev. 116, 2023–2078 (2016).
Cademartiri, L. & Bishop, Okay. Programmable self-assembly. Nat. Mater. 14, 2–9 (2015).
Wang, Y., Hu, Y. & Ye, D. Activatable multimodal probes for in vivo imaging and theranostics. Angew. Chem. Int. Ed. 61, e202209512 (2022).
Chagri, S., Ng, D. Y. W. & Weil, T. Designing bioresponsive nanomaterials for intracellular self-assembly. Nat. Rev. Chem. 6, 320–338 (2022).
Kim, J. et al. In situ self-assembly for most cancers remedy and imaging. Nat. Rev. Mater. 8, 710–725 (2023).
Liang, G., Ren, H. & Rao, J. A biocompatible condensation response for managed meeting of nanostructures in residing cells. Nat. Chem. 2, 54–60 (2010).
Zhang, Y. et al. Tuning the autophagy-inducing exercise of lanthanide-based nanocrystals by way of particular surface-coating peptides. Nat. Mater. 11, 817–826 (2012).
Jeena, M. T. et al. Mitochondria localization induced self-assembly of peptide amphiphiles for mobile dysfunction. Nat. Commun. 8, 26 (2017).
Yan, R. et al. Activatable NIR fluorescence/MRI bimodal probes for in vivo imaging by enzyme-mediated fluorogenic response and self-assembly. J. Am. Chem. Soc. 141, 10331–10341 (2019).
Feng, Z. et al. Enzyme-instructed peptide assemblies selectively inhibit bone tumors. Chem. 5, 2442–2449 (2019).
Li, J. et al. New energy of self-assembling carbonic anhydrase inhibitor: quick peptide–constructed nanofibers encourage hypoxic most cancers remedy. Sci. Adv. 5, eaax0937 (2019).
An, H. et al. A tumour-selective cascade activatable self-detained system for drug supply and most cancers imaging. Nat. Commun. 10, 4861 (2019).
Gong, N. et al. Proton-driven transformable nanovaccine for most cancers immunotherapy. Nat. Nanotechnol. 15, 1053–1064 (2020).
Pieszka, M. et al. Managed supramolecular meeting inside residing cells by sequential multistaged chemical reactions. J. Am. Chem. Soc. 142, 15780–15789 (2020).
Zhang, L. et al. Transformable peptide nanoparticles arrest HER2 signalling and trigger most cancers cell loss of life in vivo. Nat. Nanotechnol. 15, 145–153 (2020).
Borkowska, M. et al. Focused crystallization of mixed-charge nanoparticles in lysosomes induces selective loss of life of most cancers cells. Nat. Nanotechnol. 15, 331–341 (2020).
He, H., Liu, S., Wu, D. & Xu, B. Enzymatically fashioned peptide assemblies sequestrate proteins and relocate inhibitors to selectively kill most cancers cells. Angew. Chem. Int. Ed. 59, 16445 (2020).
Tune, Y. et al. Self-amplifying meeting of peptides in macrophages for enhanced inflammatory therapy. J. Am. Chem. Soc. 144, 6907–6917 (2022).
Wen, X. et al. Managed sequential in situ self-assembly and disassembly of a fluorogenic cisplatin prodrug for most cancers theranostics. Nat. Commun. 14, 800 (2023).
Guo, J. et al. Hierarchical meeting of intrinsically disordered quick peptides. Chem 9, 2530–2546 (2023).
Ji, S. et al. Focused enrichment of enzyme-instructed assemblies in most cancers cell lysosomes turns immunologically chilly tumors scorching. Angew. Chem. Int. Ed. 60, 26994 (2021).
Li, W. et al. Molecular engineering of pH-responsive NIR oxazine assemblies for evoking tumor ferroptosis by way of triggering lysosomal dysfunction. J. Am. Chem. Soc. 145, 3736–3747 (2023).
Zhu, S. et al. Lysosomal high quality management of cell destiny: a novel therapeutic goal for human ailments. Cell Dying Dis. 11, 817 (2020).
Iulianna, T., Kuldeep, N. & Eric, F. The Achilles’ heel of most cancers: concentrating on tumors by way of lysosome-induced immunogenic cell loss of life. Cell Dying Dis. 13, 509 (2022).
Wang, J. et al. Intracellular condensates of oligopeptide for concentrating on lysosome and addressing a number of drug resistance of most cancers. Adv. Mater. 34, 2104704 (2022).
Wu, C. et al. Lysosome-targeted and fluorescence-turned ‘on’ cytotoxicity induced by alkaline phosphatase-triggered self-assembly. Adv. Healthc. Mater. 11, 2101346 (2022).
Jana, B. et al. Intra-lysosomal peptide meeting for the excessive selectivity index in opposition to most cancers. J. Am. Chem. Soc. 145, 18414–18431 (2023).
Peng, J. et al. Weakly perturbative imaging of interfacial water with submolecular decision by atomic pressure microscopy. Nat. Commun. 9, 122 (2018).
Egeblad, M. & Werb, Z. New capabilities for the matrix metalloproteinases in most cancers development. Nat. Rev. Most cancers 2, 161–174 (2002).
Gamcsik, M. P., Kasibhatla, M. S., Teeter, S. D. & Colvin, O. M. Glutathione ranges in human tumors. Biomarkers. 17, 671–691 (2012).
Xie, Z. et al. Cathepsin B in programmed cell loss of life equipment: mechanisms of execution and regulatory pathways. Cell Dying Dis. 14, 255 (2023).
Bertheloot, D., Latz, E. & Franklin, B. S. Necroptosis, pyroptosis and apoptosis: an intricate recreation of cell loss of life. Cell Mol. Immunol. 18, 1106–1121 (2021).
Martens, S. et al. MLKL in most cancers: greater than a necroptosis regulator. Cell Dying Differ. 28, 1757–1772 (2021).
Yu, Y. et al. Ferroptosis: a cell loss of life connecting oxidative stress, irritation and cardiovascular ailments. Cell Dying Discov. 7, 193 (2021).
Bussi, C. et al. Lysosomal injury drives mitochondrial proteome remodelling and reprograms macrophage immunometabolism. Nat. Commun. 13, 7338 (2022).
Sharma, P. & Allison, J. P. The way forward for immune checkpoint remedy. Science 348, 56–61 (2015).
Curiel, T. et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9, 562–567 (2003).
